Interleukin-11 blockade may change displayed self-peptides and trigger immune injury
In susceptible aging-human epithelia, blocking interleukin-11 may alter protein processing and displayed self-peptide identities, allowing pre-existing memory T cells to cause persistent injury. Injury independent of the specified peptide-recognition interaction would argue against this mechanism.
Omega Point 1.5
Stage of verification
- Hypothesis published2026-10-10
- Indirect evidenceAssessed at 4 of 10
- Direct testAwaited
Map of the hypothesis
Hover over an icon or tap it to see its name.
Where in the body
Biological function
Kind of knowledge gap
A double ring marks the main placement where a group contains several values.
Target map
Every target of every published hypothesis, each with the actions a hypothesis can propose on it. The targets and the actions of this hypothesis are drawn solid.

Signalling molecule
Interleukin-11
A signalling molecule whose activity can be blocked
Where this hypothesis actsProspectively specified susceptible epithelia in aging humans
Hypotheses on this target 5
Lower level
Synthesis suppression
Neutralisation3
Supplementation
Accelerated excretion

What is proposed
Neutralisation
Block IL-11 activity
With whatNot stated in the record
HowOrthogonal epithelial IL-11 perturbations; specific agents are not stated in the record
Possible result
Possible altered self-peptide display and antigen-specific injury that offsets an independently demonstrated benefit
From the recordIL-11 blockade may change proteasomal processing and thereby change the identity of displayed self-peptides

Metabolism and energy
Ubiquitin-dependent proteasomal degradation
The breakdown of ubiquitin-marked proteins by the proteasome
Where this hypothesis actsIL-11-responsive epithelia under IL-11 blockade
Hypotheses on this target 2
Inhibition
Activation1
Function preservation
Supplementation
Feedback restoration
Direct measurement
What is proposed
Selectively prevent processing changes that alter displayed self-peptide identity
HowSelective processing intervention preserving source-protein function and epithelial fitness; broad proteasome inhibition is insufficient
Possible result
Expected prevention of the self-peptide identity change and attributable epithelial injury
From the recordSelective processing intervention should prevent the identity change and attributable injury while preserving epithelial fitness

Signalling pathway
Antigen-receptor signaling
Signaling through antigen receptors during cognate antigen recognition
Where this hypothesis actsBetween susceptible epithelia and pre-existing cognate autoreactive memory T cells during IL-11 blockade
Hypotheses on this target 4
Inhibition1
Activation
Desensitisation
Function preservation
Feedback restoration
Rhythm restoration1
What is proposed
Interrupt the implicated peptide–HLA–T-cell-receptor interaction
HowRemove and restore the interaction at endogenous-range display while preserving source-protein function and IL-11 blockade
Possible result
Expected loss of attributable epithelial killing when interrupted and return of recognition when restored
From the recordSeparately remove and restore the implicated peptide–HLA–T-cell-receptor interaction at endogenous-range display, preserving source-protein function and IL-11 blockade.
All targets of the lab
Every target read from the published hypotheses, each kind around its pictogram. A larger mark means more hypotheses act on that target. Point at a mark and the actions proposed on it branch out of it.
Solid and named: the targets of this hypothesis
Explore in depth
The logic
The train of thought that ends in this hypothesis. Each stage is the reason the next exists. The master question narrows to a goal, the goal to an unknown nobody has closed, the unknown to the hypothesis proposed here. Every step below says what it rests on and what carries it.
Reducing inflammation could still leave tissues worse off if immune cells begin attacking them. The unexpected move is that blocking interleukin-11 might change the identity of protein fragments displayed by epithelia, the cell layers covering surfaces and lining organs, and awaken an existing immune response against the body's own tissue. This is a proposal generated by the pipeline, not a measured result.
- Interleukin-11 blockade would change protein cutting by the proteasome in a susceptible epithelial population specified before testing.
- Changed cutting would change the identities of displayed self-peptides, rather than merely increase the amount of fragments already displayed.
- Previously quiet, pre-existing autoreactive memory T cells would begin recognizing the changed displays at naturally occurring amounts.
- That recognition would cause selective, repeated killing of epithelial cells.
- Repeated killing would outpace cell replacement and the mechanisms restraining immune attack, despite preserved repair ability and pathogen killing.
- The resulting injury would persist and impair tissue function.
- Persistent damage would worsen specified clinical outcomes enough to offset a separately demonstrated benefit.
A building changes the wording on its identification signs, and guards who previously left it alone begin treating it as a target. The crucial change is what the signs say, rather than how many copies are posted.
Where the picture breaks: Immune cells recognize particular molecular structures rather than read messages. Whether they attack also depends on how much is displayed, whether they can reach the tissue and whether the surrounding conditions permit a response.
- Master questionstep 01 of 04
Human aging is the target of a search for ways to slow it radically.
Rests on: The supplied goal is radical slowing of human aging; it does not establish that this is achievable.
Stated in the chain - Goal pillarstep 02 of 04
A sequence of interventions intended to slow human aging radically must be feasible to carry out.
Rests on: The master question supplies the intended outcome, which this stage turns into a question about a workable sequence of interventions.
Stated in the chain - Gap questionstep 03 of 04
Blocking interleukin-11 could suppress its intended signal yet fail to slow human aging if impaired tissue repair or defense against infection cancels the benefit of reduced inflammation.
Rests on: Assessing a workable intervention includes asking whether its harms could cancel its benefits. The preceding goal does not identify interleukin-11 as an intervention with an established human aging benefit.
AssumptionInterleukin-11 blockade is taken as a candidate whose possible benefit and compensating harm merit investigation. Neither substantial slowing of human aging nor cancellation by repair or defense costs is established by the supplied material.
- Hypothesisstep 04 of 04
Blocking interleukin-11 might change how the proteasome, the cell's protein-cutting machinery, produces self-peptides, fragments of the body's own proteins. Changed fragments displayed on epithelial cells might then be recognized by pre-existing autoreactive memory T cells, immune cells that retain a capacity to respond to particular targets from the body's own tissue. Repeated attack could cause lasting damage even while repair ability, pathogen killing and reduced inflammation are separately preserved.
Rests on: The gap supplies the possibility that tissue harm could offset a benefit. The endpoint supplies a conditional route through changed fragment identity and immune recognition, explicitly borrowing its conceptual basis from transplantation research and immunopeptidomics, the measurement of protein fragments displayed to immune cells. It shifts the proposed harm from defective repair or defense to repeated immune attack.
Stated in the chain
What is carried, and what is not. The five screened sources provide background; none directly establishes a causal link in the proposed interleukin-11-to-self-directed-injury sequence. Frontiers in Immunology (2021; S6) reports reconstructed immune receptors recognizing herpes simplex virus type 2 and a specific viral fragment, which supports the feasibility of checking target recognition but does not establish recognition of altered self-peptides, tissue killing or the proposed sequence end to end.S6
Where the reasoning is carried by something unstated · 1
- Gap question. Interleukin-11 blockade is taken as a candidate whose possible benefit and compensating harm merit investigation. Neither substantial slowing of human aging nor cancellation by repair or defense costs is established by the supplied material.
How a result here could mislead · 3
- A fragment detected only after treatment could be called a new identity even though it was already present below the measurement limit and simply became more abundant. What closes it: The proposed baseline measurements, recovery controls and explicit detection limits must constrain how much could have been present before treatment. Recognition must be compared across naturally occurring display amounts; if increased abundance of an unchanged fragment remains sufficient to explain it, identity change remains unresolved.
- Killing in a culture containing epithelial cells and T cells could be attributed to changed self-peptide recognition when it instead reflects culture stress, a direct drug effect on T cells or activation unrelated to the specified target. What closes it: The design requires epithelial-only, T-cell-only and combined cultures, along with drug-removal controls and measurements of remaining drug and pathway activity. Removing and restoring the specific interaction between the peptide, its human leukocyte antigen molecule—the cell-surface protein displaying it—and the T-cell receptor—the immune cell's recognition protein—must remove and restore attributable killing at naturally occurring display amounts.
- Short-term, target-specific killing could be read as proof that the intervention cancels an aging benefit, although replacement and immune restraint might prevent lasting damage, or no substantial aging benefit might exist to cancel. What closes it: Repeated killing, cell replacement, immune restraint and barrier function must be followed separately. Clinical consequences and their magnitude require separate evidence, alongside an independently demonstrated benefit; the supplied material specifies no duration or threshold that would establish cancellation.
What would make this wrong. In the susceptible population specified before testing, verified removal of the implicated peptide-recognition interaction without reducing the injury attributed to it would break the proposed recognition-to-injury link, provided cell fitness and general susceptibility to killing were preserved. Evidence that increased amounts of an unchanged fragment fully explain recognition would defeat the identity-switch claim while leaving broader target-specific injury possible. Absence of persistent functional damage, or damage insufficient to offset an independently demonstrated benefit, would break the proposed conclusion about cancellation.
What it would change. If the full proposal held, suppressing an inflammatory signal would not by itself establish that an intervention helps slow human aging: altered immune recognition could create a separate source of tissue damage. Evaluating a sequence of interventions would then require accounting for this injury and whether it outweighs demonstrated benefits. Even successful laboratory tests would leave its frequency, persistence and clinical magnitude in aging humans unestablished, as well as whether interleukin-11 blockade substantially slows human aging at all.
Sources read · 5
Blockade of NF-kappaB activation and donation of nitric oxide: new treatment options in inflammatory bowel disease? · Scandinavian journal of gastroenterology. Supplement · 2002
“However, NF-kappaB regulated genes are also involved in survival responses of epithelial cells. For example, inhibition of the NF-kappaB mediated induction of iNOS in epithelial cells could block important anti-apoptotic and anti-microbial survival mechanisms.”
Does not settle: This source does not test IL-11 blockade, aging-human epithelia, proteasomal processing, displayed self-peptide identity or abundance, autoreactive memory T-cell recognition and killing, persistent epithelial injury, or clinical transitions.
TGF-β1/IL-11/MEK/ERK signaling mediates senescence-associated pulmonary fibrosis in a stress-induced premature senescence model of Bmi-1 deficiency. · Experimental & molecular medicine · 2020
“These processes were inhibited by anti-IL-11 or the MEK inhibitor PD98059.”
Does not settle: The source does not establish that IL-11 blockade changes proteasomal processing, displayed self-peptide identity or quantity, antigen-presentation abundance, autoreactive memory T-cell recognition, immune killing, persistent epithelial injury, or clinical transitions in susceptible aging-human epithelia.
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. · The Biochemical journal · 1998
“The current knowledge on the signal-transduction mechanisms of these cytokines from the plasma membrane to the nucleus is reviewed.”
Does not settle: This source does not establish whether IL-11 blockade changes proteasomal antigen processing or displayed self-peptide identity or quantity in aging-human epithelia, nor whether such changes cause autoreactive memory-T-cell recognition, epithelial killing, persistent injury, functional damage, or clinical transitions.
Tissue-Resident-Memory CD8+ T Cells Bridge Innate Immune Responses in Neighboring Epithelial Cells to Control Human Genital Herpes. · Frontiers in immunology · 2021
“We now confirm and extend this finding that a portion of CD8TRM is HSV-2-specific using TCR functional reconstruction, yielding reporter cells that recognize both whole virus and a specific HSV-2 peptide.”
Does not settle: The source does not test IL-11 blockade, aging-human epithelia, proteasomal processing, self-peptide or peptide-HLA identity or abundance, autoreactive memory T-cell recognition, immune-mediated epithelial killing, persistent injury, repair capacity, immune restraint, or clinical transitions. Its cognate recognition result concerns HSV-2 antigens rather than altered self-peptides.
Peptides presented by HLA class I molecules in the human thymus. · Journal of proteomics · 2013
“The thymic peptide repertoire associated with HLA molecules must mirror the peptidome that mature T cells will encounter at the periphery, including peptides that arise from tissue-restricted antigens.”
Does not settle: This abstract does not examine IL-11 blockade, aging-human epithelia, changes in proteasomal processing or peptide identity, autoreactive memory T-cell recognition or killing, persistent epithelial injury, antigen-presentation abundance, repair capacity, immune restraint, or clinical transitions.
The gap this hypothesis explains
Two live hypotheses pull in opposite directions here, and the field has not chosen between them.
Can blocking an inflammatory signal fail to slow human aging because it also weakens repair or infection defenses?
Original wording · exactly as the pipeline generated it
Can IL-11 blockade fail to slow human aging despite suppressing its intended pathway, because impaired repair or host defense offsets reduced inflammation across tissues?
What this question is asking
The question concerns whether blocking interleukin-11, a protein that carries signals between cells, could reduce inflammation without slowing human aging. It asks whether sustained treatment could suppress that protein’s signaling yet weaken tissue repair or protection against infection enough to cancel the benefit. The relevant comparison is whether treated people accumulate damage more slowly and maintain function better than people without the treatment, while avoiding offsetting harm. The question assumes that the intended signaling and inflammation can be reduced; it treats impaired repair and infection defenses as possible explanations for failure, not established effects.
- Interleukin-11 (IL-11)
- A protein that carries signals between cells. The supplied studies link blocking its signals to reduced inflammation or scarring in some settings, but also to worse lung fluid accumulation during bacterial pneumonia; its effects cannot be treated as uniformly harmful or protective.
- Blockade, inhibition, or neutralization
- Ways of reducing a biological signal’s activity. Here they refer to interfering with interleukin-11 itself or the receptor through which it acts; these approaches need not have identical effects.
- Signaling pathway and signaling suppression
- A signaling pathway is the sequence of cellular events triggered by a message such as interleukin-11. Suppression means reducing activity in that sequence, which does not by itself demonstrate better function or slower aging.
- Inflammation
- A collection of responses to injury or threats, involving immune cells and chemical signals. It can contribute to protection and repair as well as damage, so a reduction is not automatically an overall benefit.
- Human aging
- The changes over time that affect bodily function and vulnerability to illness. This question concerns slower damage accumulation together with preserved function, rather than treating one changed signal as a complete measure of aging.
- Tissue repair and regeneration
- Repair restores injured tissue, while regeneration more specifically involves replacing or restoring its working cells. Measurements associated with regeneration can suggest activity in this process without proving complete functional recovery.
- Host defense or infection defenses
- The body's processes for resisting and controlling infection. They include more than removing bacteria, so one unchanged measure does not settle every aspect of protection.
- Acute bacterial pneumonia
- A lung infection caused by bacteria and studied over a short period. In S7, this setting revealed increased lung fluid after interleukin-11 neutralization, but it does not represent sustained treatment during aging.
- Neutrophils
- A type of immune cell involved in responses to infection and injury. S7 measured their accumulation in lung airspaces; fewer such cells did not coincide with a reported change in bacterial clearance.
- Bacterial clearance
- The removal or reduction of bacteria during infection. It was unchanged in the supplied account of S7, limiting the claim that blockade weakened antibacterial protection in that study.
- Scarring
- The buildup of scar tissue during responses to injury, also called fibrosis. Reduced scarring in the supplied mouse studies is one reported benefit, but does not establish an overall effect on human aging.
- Antibody and receptor
- An antibody is a protein that binds a particular target; a receptor is a cellular component that receives a signal. The supplied studies use antibodies against interleukin-11 or its receptor to interfere with signaling.
- Acetaminophen-induced liver injury
- Liver damage caused by acetaminophen, a medicine used for pain and fever. S5 studies this acute injury in mice, rather than ordinary aging or sustained treatment.
- Mouse model
- A study system using mice to examine a biological process or disease. Its findings establish results under those study conditions, not automatically the corresponding result in humans.
- Bone renewal
- The ongoing removal and replacement of bone tissue. S9 identifies possible interference with this process as unresolved, rather than reporting established harm.
IL-11 blockade can suppress its intended pathway and reduce inflammation across tissues, making a net benefit for human aging plausible.
Interleukin-11 is a signaling protein, and blocking it is intended to interrupt the messages it sends to cells. The question assumes this interruption can reduce inflammation in different organs, providing a benefit that possible repair or infection-related harm could offset. That assumption establishes the proposed benefit side of the comparison; it does not establish slower human aging.
S10 reports reduced inflammation and improved kidney function after interleukin-11 blockade in a mouse kidney-disease model. S4 reports improved lung repair after interruption of the same signaling system in a mouse injury model. These findings support particular beneficial effects in mice, but they do not establish sustained suppression of inflammation across human tissues or slower human aging. S8 frames effects on aging in older people as something to determine, and S2 calls for human trials. The supplied sources also do not establish the different-pathway vascular and infection tradeoff mentioned in the pipeline’s gap detail.S10S4S8S2
The same question asked without the part nothing read establishes:
- When interleukin-11 signaling is successfully blocked in humans, does aging slow, remain unchanged, or worsen overall?
- Does sustained interleukin-11 blockade preserve human function without offsetting harm to tissue repair or protection against infection?
- Benefit survives possible harms If reduced inflammation leads to less accumulating damage while repair and infection defenses remain adequate, function could be preserved for longer. Under that outcome, successful signaling suppression would accompany an overall aging benefit rather than merely a change in a biological measurement.
- Benefits and harms cancel If reduced inflammation prevents some damage but impaired repair or infection defenses cause a comparable burden, overall damage and function could remain unchanged. Successful suppression of the intended signal would then fail to establish slower aging.
- Harms outweigh benefit If impaired repair or infection defenses cause more injury than reduced inflammation prevents, function could deteriorate despite successful signaling suppression. Under that outcome, the treatment’s intended biological effect would coexist with worse overall health.
The proposed benefit starts with blocking interleukin-11 signaling, followed by less inflammation, less accumulating damage, and better preservation of function. The proposed counterweight is that treatment might also disrupt repair or protection against infection, allowing additional injury to offset those gains. These are the question’s competing causal chains; the supplied sources do not establish their balance in humans. Equating reduced signaling with slower aging could therefore mistake a biological response for an overall health benefit, while assuming repair must worsen would overlook the repair benefits reported in some mouse models.
RL-1 mouse IL-11 lifespan benefit lacks human aging outcomes; RL-2 human cytokine evidence demonstrates a different pathway's vascular/infection tradeoff.
Chronic damage slopes improve alongside function, without acute repair failure or an offsetting increase in infection and other clinical vulnerability.
Successful IL-11 target engagement could leave human aging unchanged or exchange inflammatory benefit for functional harm; the promising cross-species sufficiency inference remains falsifiable.
The mechanism it proposes
The engine's own statement of the hypothesis, in full.
SCOUT from transplant immunology and immunopeptidomics, conditional: In a prospectively specified susceptible population of aging-human epithelia, IL-11 blockade may change proteasomal processing and thereby change the identity of displayed self-peptides at comparable cell composition and total antigen-presentation abundance. Previously quiescent, pre-existing cognate autoreactive memory T cells could recognize those altered identities and impose repeated epithelial injury despite intact intrinsic repair capacity, adequate pathogen killing and reduced soluble inflammatory markers. If injury exceeds epithelial replacement and immune restraint and produces persistent functional damage, it could worsen particular SPV_3 clinical transitions and offset an independently demonstrated beneficial effect. Peptide identity is the frozen switch; increased quantity of already displayed peptides is an alternative. Processing, identity change, physiological recognition, killing, persistence and clinical consequence remain separately testable links. Finite baseline sampling may leave the identity distinction unresolved without disproving a broader antigen-specific injury mechanism.
Testing and possible results
The prediction that would tell it apart
A hypothesis that predicts what its rivals predict is not worth running an experiment over. This is the observation on which this one differs.
First establish epithelial IL-11 responsiveness and a reproducible change in endogenous displayed self-peptide species under orthogonal epithelial IL-11 perturbations. Identify peptide sequence, relevant modifications and presenting HLA molecule. Compare baseline and treated samples with quantitative recovery controls, targeted baseline measurements and explicit detection limits. Baseline non-detection cannot establish absolute absence. Constrain baseline abundance and compare it with independently characterized recognition over physiological display ranges, testing whether increased abundance of an unchanged species can explain recognition. If that account remains plausible, report identity change as unresolved; do not count new detection as confirmation or reject broader antigen-specific harm. At comparable cell composition and total presentation, the full chain predicts altered proteasomal processing before the repertoire change, recognition by a baseline memory population with independently demonstrated cognate specificity, and then selective killing. Measure source proteins, direct cleavage products, transport/loading, HLA composition, turnover and cell state. Selective processing intervention should prevent the identity change and attributable injury while preserving epithelial fitness; physiological downstream reconstitution should restore the specified peptide–HLA complex and recognition. Broad proteasome inhibition is insufficient. Separately remove and restore the implicated peptide–HLA–T-cell-receptor interaction at endogenous-range display, preserving source-protein function and IL-11 blockade. Include epithelial-only, T-cell-only, coculture, perturbation-alone and pretreatment/washout controls with residual drug and pathway-state measurements. Demonstrate baseline memory phenotype, specificity, tissue access and response under prospectively defined physiological activation support; strong artificial stimulation cannot establish the in-tissue conjunction. Measure preserved intrinsic repair, adequate laboratory pathogen killing and reduced soluble inflammatory markers separately. Follow repeated killing, replacement, immune restraint and barrier function before claiming persistent injury. Identity change without processing mediation leaves the proteasomal link open; antigen-specific killing without an identified switch supports only a partial or alternative route. Injury independent of the specified recognition pair favors stress, bystander activation or generalized susceptibility.
States a measurable outcome; comparing rivals needs more conditions. The prediction specifies an observable temporal sequence, intervention-dependent prevention and restoration, and an outcome favoring alternative mechanisms. No rival prediction is supplied. Only a bench experiment would settle it.
What testing it would take
The engine's own read on whether this is testable with methods that already exist.
Proteasomal processing is cleavage of intracellular proteins by the proteasome, generating fragments that may enter presentation pathways. HLA expands conventionally as human leukocyte antigen and denotes the human major histocompatibility system; its molecules present peptides for T-cell-receptor recognition. The relevant presenting molecules, class, alleles and genotype dependence must be identified experimentally. An epitope is the molecular feature recognized, here a defined peptide–HLA complex. A clonotype is a T-cell population identified by receptor sequence; baseline detection alone establishes neither memory phenotype nor cognate specificity. Immunopeptidomics profiles presented peptides and requires identity, recovery and detection controls. Recognition must occur at naturally achieved presentation levels. Selective processing and epitope interventions must preserve source-protein function, epithelial fitness and general susceptibility to killing. Reconstitution must reproduce endogenous-range complexes; supraphysiological peptide loading does not establish the physiological mechanism. Autologous pairing addresses allogeneic mismatch but leaves microbial recognition, bystander activation and culture stress as alternatives. Selective mediation and faithful restoration may prove technically infeasible.
Other explanations
Every other hypothesis the engine wrote for the same gap, and the observation that would separate the two.
First establish epithelial IL-11 responsiveness and a reproducible change in endogenous displayed self-peptide species under orthogonal epithelial IL-11 perturbations. Identify peptide sequence, relevant modifications and presenting HLA molecule. Compare baseline and treated samples with quantitative recovery controls, targeted baseline measurements and explicit detection limits. Baseline non-detection cannot establish absolute absence. Constrain baseline abundance and compare it with independently characterized recognition over physiological display ranges, testing whether increased abundance of an unchanged species can explain recognition. If that account remains plausible, report identity change as unresolved; do not count new detection as confirmation or reject broader antigen-specific harm. At comparable cell composition and total presentation, the full chain predicts altered proteasomal processing before the repertoire change, recognition by a baseline memory population with independently demonstrated cognate specificity, and then selective killing. Measure source proteins, direct cleavage products, transport/loading, HLA composition, turnover and cell state. Selective processing intervention should prevent the identity change and attributable injury while preserving epithelial fitness; physiological downstream reconstitution should restore the specified peptide–HLA complex and recognition. Broad proteasome inhibition is insufficient. Separately remove and restore the implicated peptide–HLA–T-cell-receptor interaction at endogenous-range display, preserving source-protein function and IL-11 blockade. Include epithelial-only, T-cell-only, coculture, perturbation-alone and pretreatment/washout controls with residual drug and pathway-state measurements. Demonstrate baseline memory phenotype, specificity, tissue access and response under prospectively defined physiological activation support; strong artificial stimulation cannot establish the in-tissue conjunction. Measure preserved intrinsic repair, adequate laboratory pathogen killing and reduced soluble inflammatory markers separately. Follow repeated killing, replacement, immune restraint and barrier function before claiming persistent injury. Identity change without processing mediation leaves the proteasomal link open; antigen-specific killing without an identified switch supports only a partial or alternative route. Injury independent of the specified recognition pair favors stress, bystander activation or generalized susceptibility.
- What would separate them
Blocking interleukin-11 may shift genome repair toward error-prone end joining predicts: Before observing repair outcomes, specify the donor population and baseline cellular eligibility, including epithelial lineage, cycling capacity and a reproducible endogenous IL-11 response measured in independent baseline aliquots. Do not define susceptibility by subsequently observing excess errors. Under randomized donor-paired control, ligand-neutralization and inducible IL11RA-loss conditions, compare characterized nonlethal lesion classes at matched genomic sites. Characterize initial break-end structure and chemistry, clustered or associated damage, complexity, local chromatin and replication context, lesion induction timing and burden. Equal break counts alone are insufficient. Combine a defined-break reporter with direct measurements at endogenous loci, including matched-site induced lesions and separately characterized ordinary endogenous damage where feasible. Follow lesion processing over time: treatment-induced end processing may itself mediate repair choice and must not automatically be matched away. Estimate the total treatment effect separately from repair accuracy under experimentally comparable initial substrates. Retain unchallenged cultures and the complete randomized starting population. The focal prediction is excess de novo structural repair errors for comparable initial lesion classes before differential expansion explains the result, with orthogonal IL-11 perturbations and a validated physiological, perturbation-compatible rescue reversing that excess. Orthogonal polymerase-theta perturbation should identify its contribution while accurate repair, other erroneous repair, persistent breaks, arrest, death and lineage loss remain accounted for per initial lesion and starting cell; descendant-level estimates are additional denominators. A reduced microhomology signature accompanied by worse unresolved damage or lineage survival does not demonstrate improved fidelity. The substrate/selection alternative predicts that differences follow lesion characteristics, lesion production, division history or lineage recovery, with equivalent accuracy for comparable substrates. If initial substrates cannot be adequately characterized or controlled, fidelity versus substrate mediation remains unresolved. Separately demonstrate reduced inflammatory injury, adequate early epithelial replacement and mature function, and preserved laboratory pathogen clearance at the same exposure. A fidelity defect alone supports only part of the frozen conjunction. Sensitive bounded equivalence constrains the prospectively defined population and tested lesion classes; it does not justify retrospectively excluding nonresponders. Receptor competition, communication defects and immune injury may coexist or lie upstream.
- What would separate them
Disrupted interleukin-11 feedback may uncouple epithelial and stromal repair predicts: First identify a native responsive older-human lung epithelial–stromal sender–receiver pair. Independently perturb sender repair state across independently varied receiver starting states while controlling initial injury, matrix, nutrients and nonspecific support. Measure whether endogenous IL-11 output changes with sender state and whether selective sender IL-11 loss and receiver IL11RA loss interrupt the attributable response, with appropriate perturbation-alone and restoration controls. Monitor other secretions, nutrient changes, matrix changes and material transport. Then randomize correct alignment versus mismatch between actual partner state and delivered IL-11-dependent signal. Compare contingent signals with yoked signals from independently assigned, appropriately matched partners, shuffled signals and state-independent schedules. Balance waveform amplitude, duration, integrated exposure, pulse statistics and relevant delay distributions where feasible, while retaining state–signal alignment as the changed variable. Measure realized receptor activation and adaptation without forcing complete mediator histories to equality. The focal prediction is that mismatch impairs complementary mature differentiation and barrier recovery and correct alignment reverses this penalty while isolated competence and lower mean inflammatory signaling remain separately verified. A favorable separation additionally requires maintained reduction in actual inflammatory injury during rescue, with cell-specific exposure, peaks and duration assessed; a lower average can conceal damaging local pulses. Equivalent recovery with an appropriately chosen state-independent schedule after receiver readiness, shared injury history and support are addressed favors the alternative that actual partner state adds no necessary guidance. Unmatched replay superiority, equal integrated ligand and pulse-versus-tonic superiority are insufficient. Demonstrated endogenous feedback supports the biological coupling claim but does not establish novelty beyond reciprocal paracrine support or validate the consensus equation. For the model, calibrate coordinates and parameters independently and predict held-out changes in sender state, communication edges, delays and mature functional recovery; compare these predictions with receiver-only exposure/support models.
- What would separate them
Interleukin-11 may reflect injury while exerting little control over human aging predicts: Test limited benefit and limited harm separately after a prospectively justified transient interval. At demonstrated tissue exposure, validated damage and functional trajectories should lie within prespecified consequential equivalence bounds, while repair, pathogen control and adverse channels independently meet their own bounds. Aggregate nonsignificance supports neither neutrality nor cancellation. If a candidate cost appears, use randomized control C, blockade B, rescue alone R and blockade-plus-rescue BR arms. Verify comparable blockade exposure and target engagement in B and BR, demonstrate adverse-mediator removal, and measure the rescue's independent effects. For Y oriented so that higher is better, estimate Δ0=Y_B−Y_C, ΔR=Y_BR−Y_R and interaction I=ΔR−Δ0. A favorable BR−B contrast does not identify blockade benefit; a favorable ΔR or interaction does not alone identify cancellation. The prediction that no consequential blockade benefit emerges under rescue is conditional on rescue preserving the relevant biological context, beneficial pathways and effect modifiers apart from removing a demonstrated blockade-induced harmful component. Test that preservation using direct mediator, cell-state, exposure and beneficial-channel measurements; rescue specificity by itself does not establish it. If rescue creates a new permissive state or interaction, benefit under rescue remains compatible with neutrality in the original setting. To support cancellation, demonstrate beneficial and harmful effects of blockade before rescue at the same exposure and relevant duration, then show selective removal of the harmful component while the beneficial route remains operative. Even with a factorial interaction, alternative synergy requires consideration. Failure to uncover benefit remains inconclusive when rescue is incomplete, context changes, exposure differs, precision is inadequate or follow-up is too short. Marker behavior, disease-specific amplification and redundancy require additional causal tests and are not identified by equivalence alone.
- Rival 04 of 04What would separate them
Blocking interleukin-11 may free shared receptors to sustain harmful competing signals predicts: In a characterized older-human epithelial population under fixed defined ligands, an occupancy-releasing blocker should produce a quantitatively compatible loss of gp130 from IL-11 complexes and gain in specified competing complexes within the same accessible pool. Resolve individual cells and relevant membrane compartments with sufficient temporal resolution to establish exchange compatibility before the competing signal and functional cost. Reciprocal population or whole-cell averages from different subpopulations or disconnected compartments are insufficient. Use convergent minimally perturbing complex and localization measurements and, where validated, tracking of component movement or a pool-selective perturbation to test access and exchange. Account for free, other-bound, incoming, internalized and recycled components rather than assume direct one-for-one transfer. Compare blocker modalities at comparable IL-11 inhibition; occupancy-retaining inhibition need not redistribute gp130. Independently demonstrate a limiting range where additional accessible surface gp130 increases competing-complex assembly and a nonlimiting range where further increases do not materially increase assembly, with adequate precision and unsaturated detection. Independently verify that downstream and functional readouts retain responsive range. Quantify receptor abundances, ratios, localization, baseline complexes and trafficking across the manipulation. Only the conjunction of same-pool allocation, validated limitation and its relief, responsive readouts and functional mediation supports competition. Controlled occupancy restoration should reverse allocation, subject to controls for its effects on signaling and trafficking. Competing-receptor interruption should remove the attributable cost while IL-11 suppression persists, with interruption-alone controls. Rescue or attenuation at high gp130 alone does not distinguish allocation from feedback, saturation or trafficking. Follow the acute step into sustained harmful differentiation or function and post-transient deterioration; neutral, beneficial or transient allocation does not confirm the harmful extension.
What stands behind it
Which of the figures above have a study behind them, which are the engine's own, and what it would take to refute the hypothesis. This audit never judges the idea.
This hypothesis states no figure and cites no study, so there is nothing here to trace.
What it would take to refute it. Nothing already retrieved carries the prediction’s terms and it names no measurement this layer can route to a public dataset, so the bench is the residual — not a finding against it.
1 paper retrieved around this hypothesis
- Abstracts from the 57th European Society of Human Genetics (ESHG) Conference: Hybrid Posterseuropepmc:PMC:PMC11627200 · unavailable · 0 characters stored
0 citation handles extracted; 1 Europe PMC search run; 1 records examined; 1 sources stored for enrichment, 0 with full text. A citation that did not resolve is a bibliographic failure, not proof that no such paper exists, and no hypothesis is blocked by this audit.